CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns

CNS Pharmaceuticals, Inc.

Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.
John Climaco resigned as CEO and board member Dec 16, 2025; resignation not due to disagreement; severance includes 12 months salary and $319,000 bonus.
Levin will also join the board; previously CEO of Saniona (2019-2022) and ImStem Biotechnology (2022-2024).
If Levin is terminated without cause or for good reason, severance includes 12 months base salary, target bonus, accelerated equity vesting, and COBRA subsidy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.